Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12222332 | 0.89 | FFAR1 (0.48) | FFAR1RXRARXRBPTGS2SLC13A5 | |
| SCHEMBL2505833 | 0.87 | FFAR1 (0.46) | FFAR1RXRARXRBPTGS2SLC13A5 | |
| SCHEMBL2310765 | 0.86 | FFAR1 (0.53) | FFAR1KDM4ECYP3A4ALDH1A1HPGD | |
| SCHEMBL12191922 | 0.85 | FFAR1 (0.47) | FFAR1RXRARXRBPTGS2SLC13A5 | |
| SCHEMBL30129226 | 0.80 | MEN1 (0.43) | GAA | |
| SCHEMBL2499065 | 0.78 | FFAR1 (0.65) | FFAR1 | |
| SCHEMBL2499987 | 0.78 | RXRA (0.51) | FFAR1RXRARXRBPTGS2GAA | |
| SCHEMBL27587232 | 0.77 | FFAR1 (0.46) | FFAR1NR1H2NR1H3 | |
| SCHEMBL4759655 | 0.77 | RXRA (0.63) | FFAR1RXRARXRBSLC13A5KDM4E | |
| SCHEMBL12221333 | 0.77 | FFAR1 (0.53) | FFAR1KDM4EGAAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2260017-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | FFAR1 18/4885RXRA 114/4885RXRB 73/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | FFAR1 171/4885RXRA 694/4885RXRB 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.